Le patch VIASKIN ® Peanut a été bien toléré ; la majorité des événements indésirables survenus pendant le traitement (TEAE) étaient des réactions locales légères au site d'application, conformément ...
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN ® Peanut Patch increased their ...
Bezuclastinib demonstrates consistent biomarker and symptomatic improvement in patients with smoldering SM, a subgroup of NonAdvSM with high unmet need. As previously reported, bezuclastinib ...
Positioned as the "value king of high-capacity fast-charging power banks," the CUKTECH 25SE perfectly addresses Malaysia's growing need for efficient and reliable power solutions. Its core strength ...
Zhou Feng, Chief Strategy Officer of Fangzhou, commented, “The collaboration represents both complementary strengths and a step toward building a new healthcare ecosystem,” adding that the company ...
Informational 2026 customer report evaluates ReduBurn marketing claims, ingredient transparency, thermogenic resistance framing, pricing structure, published refund terms, and consumer due diligence ...
NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”) will release its results for the fourth quarter and full year 2025 ended December ...
These inducement grants were granted at an exercise price per share of $0.50 and $0.57, equal to the closing price of Femasys common stock on the date of employment as reported by Nasdaq. This grant ...
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization
Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen ...
Details for the Company’s participation are as follows: Fireside Chat: Monday, March 2, 2026 at 1:50 p.m. ET The webcast for this conference may be accessed via the “ Events ” section of the Company’s ...
Based on the ongoing activities in the ARD-101 program, Aardvark no longer anticipates announcing topline data from the HERO trial in the third quarter of 2026 and expects to provide further guidance ...
In addition, Dr. Shaltiel will be speaking at the Advanced Therapies Congress in London in March 2026, Europe’s largest commercial cell and gene therapy conference and exhibition. The congress brings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results